— Know what they know.
Not Investment Advice
Also trades as: NRXP (NASDAQ) · $vol 3M

NRXPW NASDAQ

NRx Pharmaceuticals, Inc.
1W: -49.5% 1M: +0.0% 3M: -84.9% YTD: -92.2% 1Y: -94.1% 3Y: -97.7% 5Y: -97.3%
$0.01
-0.00 (-12.94%)
 
Weekly Expected Move ±102.6%
$-0 $-0 $0 $0 $0
NASDAQ · Healthcare · Biotechnology · Alpha Radar Sell · Power 49 · $188536 mcap · 29M float · 0.067% daily turnover · Short 48% of daily vol
Smart Money Score
No convergence signal
Key Statistics
Market Cap$0.2M
52W Range0.0051-0.1602
Volume23,367
Avg Volume19,460
Beta1.73
Dividend
Analyst Ratings
2 Buy 0 Hold 0 Sell
Consensus Buy
Company Info
CEOJonathan C. Javitt
Employees10
SectorHealthcare
IndustryBiotechnology
IPO Date2017-12-01
1201 Orange Street
Wilmington, DE 19801
US
484 254 6134
About NRx Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Recent Insider Trades

NameTypeSharesPriceDate
Casper Joseph Michae A-Award 100,000 $2.39 2026-01-27
Casper Joseph Michae 100,000 $2.39 2026-01-27
B Group, Inc. 0 2025-08-18
Javitt Jonathan C A-Award 125,000 $1.73 2025-04-09
McBride Dennis A-Award 25,000 $1.73 2025-04-09

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms